Navigation Links
Sangamo BioSciences Announces Research Collaboration With UCLA in Human Stem Cells Selected to Receive Clinical Research Award
Date:10/1/2009

RICHMOND, Calif., Oct. 1 /PRNewswire-FirstCall/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) announced today that research led by Donald B. Kohn, M.D., Professor of Microbiology, Immunology and Molecular Genetics (MIMG) and Pediatrics, the Director of the UCLA Human Gene Medicine Program and member of the Broad Stem Cell Research Center, and Philip Gregory, D. Phil., Sangamo's chief scientific officer and vice president, research, has been selected to receive a $486,000 Doris Duke Innovations in Clinical Research Award from the Doris Duke Charitable Foundation. The grant, which will be paid over three years, will support an innovative research project conducted by Dr. Kohn and Sangamo scientists and titled "Beta-globin Gene Correction in Hematopoietic Stem Cells for Sickle Cell Disease."

"ZFN-mediated gene editing is an exciting and now proven technology with the potential to provide a solution for sickle cell anemia and other hemoglobinopathies," said Dr. Kohn. "Despite the fact that sickle-cell anemia was the first genetic disorder for which a molecular cause was identified and one in which every patient has the same gene mutation, the lack of treatment options makes the disease a hugely important problem worldwide. This novel approach will develop the use of efficient ZFN-mediated correction of the sickle mutation in the human beta-globin gene in stem cells from patients with sickle cell disease rather than traditional approaches of gene replacement therapy."

The Doris Duke Innovations in Clinical Research Award (ICRA) provides seed funding for early stage, multi-disciplinary clinical research projects. The 2009 ICRA grants will support a range of approaches to improving the health of patients with sickle cell disease. The research proposed by Dr. Kohn and Sangamo is one of five projects selected to receive grants from t
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
2. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
3. Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
4. Sangamo BioSciences and Sigma-Aldrich Announce Publication of Study Demonstrating Zinc Finger Technology for Rapid Generation of Knock-Out Cell Lines
5. Sangamo BioSciences Announces Presentation of Data on ZFP Therapeutic for Glioblastoma at American Association for Cancer Research (AACR) Meeting
6. Sangamo BioSciences Provides Update on Diabetic Neuropathy Clinical Programs
7. Sangamo BioSciences Announces Presentation of Phase 1b ZFP Therapeutic Data at American Diabetes Association Meeting
8. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant T Cells
9. Sangamo BioSciences Initiates Phase 2 Clinical Trial of Treatment for Amyotrophic Lateral Sclerosis (ALS)
10. Sangamo BioSciences Provides Update on Companys 2008 Progress and 2009 Objectives
11. Sangamo BioSciences Announces Presentations at Two Upcoming Investor Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/5/2015)... 2015  As the pharmaceutical industry works to ... Compliance professionals are placing a significant emphasis on ... today by LRN, the leader in Ethics & ... of respondents expressed that clarity on company values ... E&C training programs (57%), trumping understanding of the ...
(Date:3/5/2015)... 2015 Bayer HealthCare announced today that it ... Foundation of the American Society of Clinical Oncology (ASCO) ... platform designed to unlock vast quantities of information about ... "Bayer is proud to join ASCO and the ... Data to help people whose lives have been affected ...
(Date:3/5/2015)... -- Sanomedics, Inc. (OTC: SIMH, SIMHD) ("Sanomedics" or the "Company"), ... and acquiring cutting-edge technology, products and services announced today ... at booth # 709 at the National Association ... on March 11-13, 2015 at Caesars Palace in ... The 36 th annual NAPNAP Conference will bring ...
Breaking Medicine Technology:Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 2Pharmaceutical Ethics & Compliance Professionals Place Company Values Front and Center 3Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 2Bayer HealthCare Contributes $1 Million to Support Cancer Care Technology Platform 3Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 2Sanomedics to Showcase the Caregiver at National Association of Pediatric Nurse Practitioners Conference 3
... 24, 2011 Genelux Corporation, a privately held, clinical ... cancer and inflammatory diseases, today announced the appointment of ... Board of Directors. Dr. Fenton,s appointment expands the Genelux ... someone who helped to build one of the world,s ...
... VIEW, Calif., Jan. 24, 2011 Based on its ... market, Frost & Sullivan recognizes BeClose with the 2010 ... of the Year for its innovative BeClose System and ... (Logo:   http://photos.prnewswire.com/prnh/20081117/FSLOGO ) While PERS have ...
Cached Medicine Technology:Genelux Corporation Expands Board of Directors, Appointing Dennis Fenton, Former Amgen Executive 2Frost & Sullivan Recognizes BeClose as a Technology Innovator for 'Aging Independently' in North America 2Frost & Sullivan Recognizes BeClose as a Technology Innovator for 'Aging Independently' in North America 3Frost & Sullivan Recognizes BeClose as a Technology Innovator for 'Aging Independently' in North America 4
(Date:3/5/2015)... March 05, 2015 Central Nebraska Imaging ... practice including the brand’s new logo and optimized website. ... the practice’s modern approach to expert diagnostic imaging, centered ... and be built to be a resource for Nebraska ... With automated forms, communication and referral functionality, video content ...
(Date:3/5/2015)... On March 2, 2015, NBC News ... the Rise, Plastic Surgeons Say,” that comments on the ... Aesthetic Plastic Surgery and the American Society ... year-over-year doubling of surgical butt augmentations performed in 2014. ... article, this increase can be attributed to the social ...
(Date:3/5/2015)... At the 7th Annual Mississippi Addiction ... treatment met today in Jackson, Mississippi to listen to ... the numerous respected speakers will be William S. ... that pain medications have had in today’s opiate overdose ... "It is hard to believe that much of the ...
(Date:3/5/2015)... Ore. (PRWEB) March 05, 2015 ... sciences university founded in 1904, has launched a ... and positive lifestyle changes. The Northwest Center for ... health professionals, support community outreach, and conduct research ... functional medicine, diet and nutrition. The center will ...
(Date:3/5/2015)... Dr. Jonathan Glashow a board certified New ... named by Castle Connolly as a Top ... has been selected by Castle Connolly Medical Ltd. for ... care doctors in the tri-state metropolitan New York area ... carefully screens and selects doctors through a rigorous peer ...
Breaking Medicine News(10 mins):Health News:Central Nebraska Imaging Center Gets Rebranding 2Health News:The Kim Kardashian and Jennifer Lopez Effect: Butt Augmentations Double from 2013 to 2014 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 2Health News:National Addiction Treatment Expert William S. “Bill” Jacobs, Md Speaks At Prestigious 7th Annual Mississippi Addiction Conference 3Health News:University of Western States Launches Northwest Center for Lifestyle and Functional Medicine 2Health News:Dr. Jonathan Glashow, NYC Orthopedic Surgeon, Named Top Doctor: New York Metro Area 2
... these conditions go untreated , , MONDAY, May 12 (HealthDay News) ... are bad for your heart, they may also harm your ... to increase one,s risk for retinal vein occlusion, a condition ... more veins carrying blood from the eye to the heart ...
... PITTSBURGH Carnegie Mellon Universitys Justin Y. Newberg and Robert F. Murphy have ... protein patterns in human tissues., ... student in biomedical engineering, described the automated protein pattern recognition tool and ... for cancer diagnosis and therapy. , ...
... Damir Matic, a scientist with Lawson Health Research Institute in ... performed throughout North America and around the world. Matic ... close the gum tissue of cleft palate patients. His research ... is older. , Matic is a craniofacial/plastic surgeon at London ...
... U.S. survey estimates 750,000, mostly males, are hooked , , ... American teens and young adults are problem gamblers according ... on Addictions. , Problem gambling is defined as ... as gambling more than you intended or stealing money ...
... OmniSonics Medical,Technologies, Inc., a developer of advanced medical ... announced today that it has enrolled its,first patient ... a prospective,multi-center U.S. registry study of the company,s ... thrombectomy,for acute limb ischemia (ALI). All patients enrolled ...
... BETHESDA, Md., May 12 Naturlose, a natural sugar,approved as ... found to,reduce the spikes of serum glucose that follow consumption ... (Nasdaq: SPEX ) is currently,studying the efficacy and safety ... trial is ongoing, Spherix has engaged market,research companies to seek ...
Cached Medicine News:Health News:High Blood Pressure, Cholesterol Associated With Eye Disease 2Health News:Carnegie Mellon engineering researchers automate analysis of protein patterns 2Health News:Research shows timing improves cleft palate surgery 2Health News:Problem Gambling Common Among Young Adults 2Health News:OmniSonics Medical Technologies Announces First Patient Enrolled in SONIC II REGISTRY 2Health News:Market Research Shows Spherix's Naturlose(R) Readily Accepted by Diabetes Patients 2Health News:Market Research Shows Spherix's Naturlose(R) Readily Accepted by Diabetes Patients 3
... assayed quality control material used for ... electrolyte, metabolite, and CO-Oximeter instrumentation. The ... it the ideal choice for Bayer ... in three (3) levels for monitoring ...
RNA1c Control is an assayed quality control material used for monitoring the performance of Bayer DCA Analyzers that measure Hemoglobin A1c. It may be used on DCA 2000 and 2000+ analyzers....
... is an assayed quality control material ... blood gas, electrolyte, metabolite, and CO-Oximeter ... control makes it the ideal choice ... is available in three (3) levels ...
Cormet Hip Resurfacing is a conservative treatment for the young, active, high demand patient group which conserves femoral bone, provides anatomical bone loading, eliminates polyethylene and is desi...
Medicine Products: